| ARES-TRADING-S-A |
ARES-TRADING-S-A |
90%
|
If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV |
BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV |
90%
|
If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG |
NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG |
90%
|
If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| OFCF-II |
OFCF-II |
90%
|
The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| OFCF-III |
OFCF-III |
90%
|
The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| OFCF-IV |
OFCF-IV |
90%
|
With respect to the new lender, OFCF IV, the Company accounted for this transaction as an issuance of debt |
| OXFORD-FINANCE |
OXFORD-FINANCE |
90%
|
The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| AUPH |
Aurinia Pharmaceuticals Inc. |
72%
|
experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| AUPH |
Aurinia Pharmaceuticals Inc. |
72%
|
Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: experienced any significant delays … |
| SNYNF |
Sanofi |
72%
|
experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance th… |
| TVTX |
Travere Therapeutics, Inc. |
72%
|
experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| TVTX |
Travere Therapeutics, Inc. |
72%
|
Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance tha… |
